|Bid||7.23 x 200|
|Ask||7.24 x 700|
|Day's Range||7.13 - 7.30|
|52 Week Range||6.51 - 28.11|
|PE Ratio (TTM)||-1.57|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
On Jun 20 2017, we issued an updated research report on Pittsburgh, PA-based GNC Holdings, Inc. (GNC).
The CEO of Cardax Inc. said the selection of the company's astaxanthin compound CDX-085 to take part in the National Institute on Aging's anti-aging interventions testing program will have positive implications for the Hawaii-based business. The program, among the top aging research programs in the U.S., is funded by the National Institutes of Health and only selects 4-5 compounds every year through extensive screening for their potential impact on lifespan extension and their ability to delay disease and dysfunction in mice at different ages. "The NIH is about a $38 billion annual budget and their science is very serious and credible and the fact that they would choose our compound I think speaks to the credibility of our whole program" Cardax President and CEO David Watumull told Pacific Business News.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for GNC Holdings, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)